Advance Metals Limited (AVM) ORDINARY FULLY PAID |
Materials |
$11 |
Application for quotation of securities - AVM
|
11 Aug 2025 8:24AM |
$0.045 |
$0.041 |
fallen by
8.89%
|
|
Advance Metals Limited (AVM) ORDINARY FULLY PAID |
Materials |
$11 |
Cleansing Prospectus
|
11 Aug 2025 8:24AM |
$0.045 |
$0.041 |
fallen by
8.89%
|
|
Sprintex Limited (SIX) ORDINARY FULLY PAID |
Consumer Discretionary |
$30 |
Application for quotation of securities - SIX
|
11 Aug 2025 8:24AM |
$0.045 |
$0.047 |
risen by
4.44%
|
|
Peak Rare Earths Limited (PEK) ORDINARY FULLY PAID |
Materials |
$144 |
Court approves convening of Scheme Meeting
|
11 Aug 2025 8:23AM |
$0.335 |
$0.335 |
fallen by
0%
|
|
PEK - Price-sensitive ASX Announcement
Full Release
Key Points
- The Supreme Court of Western Australia has approved the convening of a Scheme Meeting for Peak Rare Earths Limited shareholders.
- The Scheme Meeting is scheduled for 9 August 2024.
- Under the scheme, Shenghe Resources (Hong Kong) Limited will acquire all shares in Peak Rare Earths Limited.
- The Peak Board unanimously recommends the scheme in the absence of a superior proposal.
- A Scheme Booklet containing details of the scheme will be sent to shareholders and made available online.
- The Scheme Booklet includes an independent expert’s report and details regarding the background, implications, and timeline of the transaction.
- Shareholders are encouraged to read the Scheme Booklet and vote at the Scheme Meeting.
- If approved, the transaction will result in Peak Rare Earths Limited becoming a wholly owned subsidiary of Shenghe Resources (Hong Kong) Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Gold Mountain Limited (GMN) ORDINARY FULLY PAID |
Materials |
$7 |
Presentation - Brazilian Critical Minerals for Clean Energy
|
11 Aug 2025 8:23AM |
$0.059 |
$0.059 |
fallen by
0%
|
|
Gold Mountain Limited (GMN) ORDINARY FULLY PAID |
Materials |
$7 |
Presentation - Drilling REE for the Clean Energy Transition
|
11 Aug 2025 8:23AM |
$0.059 |
$0.059 |
fallen by
0%
|
|
Linius Technologies Limited (LNU) ORDINARY FULLY PAID |
Information Technology |
$10 |
Linius Secures $250,000 Captivate Contract
|
11 Aug 2025 8:23AM |
$0.001 |
$0.002 |
risen by
50%
|
|
LNU - Price-sensitive ASX Announcement
Full Release
Key Points
- Linius Technologies Limited secured a $250,000 contract with Captivate.
- The contract involves the implementation of Linius’ Whizzard product for video search and assembly.
- Captivate specializes in digital workplace solutions for the legal sector.
- The agreement includes initial license fees and a 12-month minimum revenue guarantee.
- This is the first six-figure Whizzard contract for Linius.
- The contract is expected to deliver scalable recurring revenues.
- Linius will support Captivate in delivering enhanced video management solutions to legal clients.
- The partnership is anticipated to drive product adoption and financial growth for Linius.
- The collaboration expands Linius’ presence and influence in the legal vertical.
- Linius considers this contract a strategic milestone toward broader commercialization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
DY6 Metals Ltd (DY6) ORDINARY FULLY PAID |
Materials |
$29 |
XRF analysis confirms high-quality of natural rutile
|
11 Aug 2025 8:23AM |
$0.310 |
$0.320 |
risen by
3.23%
|
|
DY6 - Price-sensitive ASX Announcement
Full Release
Key Points
- DY6 Metals Ltd (DY6) announced that XRF analysis confirms the high-quality of natural rutile from its Machinga Project in Malawi.
- XRF (X-ray fluorescence) analysis on rutile samples demonstrates high titanium dioxide (TiO2) content and low impurity levels.
- The natural rutile is characterized by a TiO2 content of up to 97.8%, which is considered high quality for commercial purposes.
- Impurities such as iron oxide (Fe2O3), chromium oxide (Cr2O3), and vanadium oxide (V2O5) are reported to be low, supporting the premium quality of the rutile.
- The Company highlights the potential for the Machinga Project to become a significant supplier of high-quality natural rutile.
- Natural rutile is a critical mineral used in the production of titanium metal, welding electrodes, and as a feedstock for pigments.
- DY6 Metals Ltd plans further exploration and test work to define the extent and commercial viability of the rutile mineralization.
- The announcement reinforces DY6's commitment to advancing the Machinga Project and contributing to global supply chains of critical minerals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Variscan Mines Limited (VAR) ORDINARY FULLY PAID |
Materials |
$4 |
August Investor Webinar
|
11 Aug 2025 8:22AM |
$0.006 |
$0.005 |
fallen by
16.67%
|
|
Cash Converters International (CCV) ORDINARY FULLY PAID |
Financials |
$213 |
CCV Australian Store Acquisitions
|
11 Aug 2025 8:22AM |
$0.330 |
$0.340 |
risen by
3.03%
|
|
CCV - Price-sensitive ASX Announcement
Full Release
Key Points
- CCV has agreed to acquire up to 19 franchised stores in Australia to strengthen its corporate network.
- The acquisitions follow the recent successful purchase of 9 stores in South Australia.
- Transaction completion is dependent on due diligence, regulatory approvals, and agreement with franchisees.
- The acquisitions are expected to increase group revenue, EBITDA, and create operational efficiencies.
- CCV's strategy focuses on building a leading, integrated Australian retail network.
- The company reports positive trading updates, including revenue and profit growth across its segments.
- CCV emphasizes disciplined capital management and delivering shareholder returns.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Astral Resources NL (AAR) ORDINARY FULLY PAID |
Materials |
$236 |
High-Grade Gold Identified Within Kamperman Pit Shell
|
11 Aug 2025 8:22AM |
$0.170 |
$0.165 |
fallen by
2.94%
|
|
AAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Astral Resources NL has identified high-grade gold mineralisation within the Kamperman Pit Shell at the Mandilla Gold Project.
- The Mandilla Gold Project is located near Kalgoorlie in Western Australia.
- Recent drilling has intersected thick, high-grade gold zones near the surface at the Kamperman prospect.
- Significant gold assay results have been reported, supporting the potential for open pit mining.
- The results increase confidence in the resource growth potential and viability of the Kamperman area.
- Ongoing exploration activities continue to test extensions and new targets within the project.
- Further drilling and technical studies are planned to advance the resource base and project development.
- The Kamperman prospect is seen as a key component of Astral's regional development strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
IRIS Metals Limited (IR1) ORDINARY FULLY PAID |
Materials |
$21 |
Ceasing to be a substantial holder - NASDAQ
|
11 Aug 2025 8:22AM |
$0.086 |
$0.092 |
risen by
6.98%
|
|
News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,835 |
Notification of cessation of securities - NWS
|
11 Aug 2025 8:22AM |
$51.450 |
$50.210 |
fallen by
2.41%
|
|
News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,835 |
Notification of cessation of securities - NWS
|
11 Aug 2025 8:22AM |
$51.450 |
$50.210 |
fallen by
2.41%
|
|
Invex Therapeutics Ltd (IXC) ORDINARY FULLY PAID |
Health Care |
$7 |
Appendix 4E and Annual Report to shareholders
|
11 Aug 2025 8:22AM |
$0.090 |
$0.090 |
fallen by
0%
|
|
IXC - Price-sensitive ASX Announcement
Full Release
Key Points
- Invex Therapeutics Ltd is focused on developing Presendin for conditions involving raised intracranial pressure, including IIH.
- During FY2023, Invex made significant progress in its Phase III IIH EVOLVE clinical trial, with approvals and site initiations in Europe, the UK, and Australia.
- The company reported a net loss of $6,978,822 for the financial year ending 30 June 2023.
- Invex had a cash balance of $22,490,728, providing a strong runway for ongoing operations.
- No dividends were paid or proposed for the period.
- Key risks identified include regulatory, clinical, intellectual property, supply chain, and commercialisation risks.
- The company maintains a focused drug development strategy, leveraging its intellectual property portfolio and experienced management team.
- Invex expects continued advancement in clinical trials and regulatory interactions through the coming year.
- The board and management remain committed to transparent reporting and prudent financial management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$63,469 |
Notice of Proposed Sale of Securities
|
11 Aug 2025 8:22AM |
$127.090 |
$112.325 |
fallen by
11.62%
|
|
ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$63,888 |
Resmed Form 10-K Annual Report
|
11 Aug 2025 8:21AM |
$43.020 |
$43.650 |
risen by
1.46%
|
|
RMD - Price-sensitive ASX Announcement
Full Release
Key Points
- ResMed Inc. is a global leader in cloud-connected medical devices and digital health solutions focused on sleep apnea, COPD, and chronic disease management.
- The company’s product offerings include CPAP and bilevel devices, masks, ventilators, and connected health platforms.
- ResMed emphasizes innovation and R&D to expand its solutions for healthcare providers, patients, and payers.
- The report outlines numerous business risks, including regulatory compliance, competition, litigation, supply chain challenges, and economic uncertainties.
- ResMed operates in highly regulated markets and faces risks from changes in reimbursement, legislation, and international regulations.
- The company’s competitive advantages include strong brand recognition, intellectual property, and strategic acquisitions.
- Management’s Discussion and Analysis (MD&A) reviews financial performance, trends, and key metrics for the fiscal year.
- The report discusses the impact of global events, such as ongoing supply chain pressures, inflation, and foreign currency fluctuations.
- ResMed is committed to ESG (Environmental, Social, and Governance) initiatives and outlines goals in sustainability and corporate responsibility.
- The document provides details on executive compensation, shareholding structures, and governance practices.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Capstone Copper Corp. (CSC) CDI 1:1 FOREIGN EXEMPT TSX |
Materials |
$9,168 |
Capstone Copper Announces Sanctioning of MVO Project
|
11 Aug 2025 8:21AM |
$9.660 |
$9.655 |
fallen by
0.05%
|
|
Mineral Resources Limited (MIN) ORDINARY FULLY PAID |
Materials |
$7,301 |
Becoming a substantial holder
|
11 Aug 2025 8:21AM |
$33.980 |
$37.150 |
risen by
9.33%
|
|
NEXTDC Limited (NXT) ORDINARY FULLY PAID |
Information Technology |
$9,276 |
Becoming a substantial holder
|
11 Aug 2025 8:21AM |
$14.510 |
$14.485 |
fallen by
0.17%
|
|
New World Resources Limited (NWC) ORDINARY FULLY PAID |
Materials |
$243 |
Change in substantial holding
|
11 Aug 2025 8:21AM |
$0.067 |
$0.067 |
fallen by
0%
|
|
Mac Copper Limited (MAC) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$1,531 |
SARB Approval Received
|
11 Aug 2025 8:21AM |
$18.530 |
$18.550 |
risen by
0.11%
|
|
MAC - Price-sensitive ASX Announcement
Full Release
Key Points
- Mac Copper Limited received South African Reserve Bank (SARB) approval for a key transaction.
- SARB approval is required for compliance with South African exchange control regulations.
- The transaction cannot be implemented without this regulatory approval.
- The company highlights its commitment to adhering to legal and financial standards.
- Stakeholders will be kept informed of further developments regarding the transaction.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
SPDR S&P/ASX 200 Fund (STW) |
Financials |
$6,150 |
Daily Fund Update
|
11 Aug 2025 8:20AM |
$79.120 |
$79.540 |
risen by
0.53%
|
|
SPDR S&P/ASX 200 Listed Property Fund (SLF) |
Financials |
$580 |
Daily Fund Update
|
11 Aug 2025 8:20AM |
$14.290 |
$14.310 |
risen by
0.14%
|
|
SPDR S&P/ASX 50 Fund (SFY) |
Financials |
$778 |
Daily Fund Update
|
11 Aug 2025 8:20AM |
$76.900 |
$77.470 |
risen by
0.74%
|
|